- Advertisement -
CHICAGO–(BUSINESS WIRE)–Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced an expanded Series A and new appointments to its executive leadership team, board of directors and scientific advisory board. The expansion brings Syntax Bio’s…
Click here to view the original article.
